EU Medicines Agency Panel Recommends Fortvita's Lung Cancer Drug Zybrivo for Approval

MT Newswires · 1d ago
07:01 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended for approval Fortvita Biologics (Ireland)'s non-squamous non-small cell lung cancer drug Zybrivo. Zybrivo, or sintilimab, in combination with chemotherapy, improved first-line progression-free survival in adults with non-squamous non-small cell lung cancer, compared with chemotherapy alone, according to a Friday notice. The drug is subject to a final marketing authorization decision by the European Commission.